首页> 外文期刊>Infection and immunity >Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.
【24h】

Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.

机译:鼻内和肌内蛋白体-葡萄球菌肠毒素B(SEB)类毒素疫苗:免疫原性和抗小鼠致命SEB中毒的功效。

获取原文
获取外文期刊封面目录资料

摘要

Intranasal or intramuscular (i.m.) immunization of mice and i.m. immunization of rabbits with formalinized staphylococcal enterotoxin B (SEB) toxoid in saline elicited higher anti-SEB serum immunoglobulin G (IgG) titers when the toxoid was formulated with proteosomes. In addition, intranasal immunization of mice with this proteosome-toxoid vaccine elicited high levels of anti-SEB IgA in lung and intestinal secretions, whereas the toxoid without proteosomes did not. Two i.m. immunizations with proteosome-toxoid plus alum also induced higher murine serum responses than alum-adjuvanted toxoid without proteosomes. Furthermore, proteosome-toxoid delivered intranasally in saline or i.m. with either saline or alum afforded significant protection against lethal SEB challenge in two D-galactosamine-sensitized murine models of SEB intoxication, i.e., the previously described i.m. challenge model and a new respiratory challenge model of mucosal SEB exposure. Efficacy correlated with the induction of high serum levels of anti-SEB IgG. In contrast, intranasal or i.m. immunization with toxoid in saline without proteosomes was not significantly protective in either challenge model. Proteosome-toxoid plus alum given i.m. also elicited more significant protection against respiratory challenge than the alum-adjuvanted toxoid alone. The capacity of proteosomes to enhance both i.m. and intranasal immunogenicity and efficacy of SEB toxoid indicates that testing such proteosome-SEB toxoid vaccines in the nonhuman primate aerosol challenge model of SEB intoxication prior to immunogenicity trials in humans is warranted. These data expand the applicability of the proteosome mucosal vaccine delivery system to protein toxoids and suggest that respiratory delivery of proteosome vaccines may be practical for enhancement of both mucosal and systemic immunity against toxic or infectious diseases.
机译:小鼠的鼻内或肌内(i.m.)免疫和i.m.当用蛋白体配制类毒素时,用盐水中的福尔马林化葡萄球菌肠毒素B(SEB)类毒素免疫家兔会产生更高的抗SEB血清免疫球蛋白G(IgG)效价。另外,用这种蛋白体-类毒素疫苗对小鼠进行鼻内免疫可在肺和肠分泌物中引起高水平的抗SEB IgA,而没有蛋白体的类毒素则不能。两点蛋白体类毒素加明矾的免疫也比不含蛋白体的明矾类佐剂产生的鼠血清应答更高。此外,蛋白体-类毒素在盐水或i.m.中鼻内递送。在两个D-半乳糖胺致敏的SEB中毒鼠模型中,即盐水或明矾中的盐溶液提供了显着的抗致命SEB攻击的保护,即先前描述的i.m.挑战模型和粘膜SEB暴露的新的呼吸挑战模型。功效与抗SEB IgG高血清水平的诱导有关。相反,鼻内或上午在两种蛋白质挑战模型中,在无蛋白体的盐水中用类毒素进行的免疫接种均无明显保护作用。蛋白质体类毒素加明矾与单独使用明矾的类毒素相比,它也引起了对呼吸道挑战的更重要的保护。蛋白质体增强两者的能力SEB类毒素的鼻内免疫原性和功效表明,在人类进行免疫原性试验之前,有必要在SEB中毒的非人类灵长类气溶胶激发模型中测试这种蛋白体-SEB类毒素疫苗。这些数据扩展了蛋白体粘膜疫苗递送系统对蛋白类毒素的适用性,并表明蛋白体疫苗的呼吸递送对于增强针对毒性或传染性疾病的粘膜和全身免疫性可能是实用的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号